LivaNova plc (LIVN) Misses Q1 EPS by 10c, Revenues Miss; Updated FY20 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Livanova (LIVN) PT Lowered to $65 at Piper Sandler
April 29, 2020 3:39 PM EDTPiper Sandler analyst Matt O'Brien lowered the price target on Livanova (NASDAQ: LIVN) to $65.00 (from $80.00) while maintaining an Overweight rating.
negative commentary and outlook but lots value trapped in the stock... MoreLivaNova plc (LIVN) Bi-Flow Cannula Receives CE Mark for ECMO Applications
April 27, 2020 9:07 AM EDTLivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for ECMO procedures where femoral artery cannulation can be applied. Bi-Flow previously received CE Mark in 2019 for cardiac surgery procedures requiring femoral artery cannulation. Now validated for up to 29 days of use, Bi-Flow ECMO is designed to reduce the risk of limb ischemia for patients receiving ECMO and it allows for safe, easy and reproducible procedures.
After witnessing the potential of Bi-Flow in the cardiac surgery setting, the... More
